Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: the Fremantle Diabetes Study Phase II

Emma J. Hamilton, Wendy A. Davis, Ashley Makepeace, E.M. Lim, Bu B. Yeap, Kirsten E. Peters, Timothy M. E. Davis

    Research output: Contribution to journalArticle

    11 Citations (Scopus)


    © 2016 John Wiley & Sons Ltd

    Background: Because published studies have usually involved imprecise assays and selected patients with limited additional data and follow-up, the consequences of a low serum testosterone in diabetes are unclear. This study assessed the prevalence, associates and prognosis of a low testosterone in community-dwelling men with type 2 diabetes. Design: Longitudinal observational study. Patients: 788 men (mean ± SD age: 65·8 ± 11·3 years) followed for 4·0 ± 1·1 years. Measurements: Serum testosterone, SHBG, erectile dysfunction (ED; Sexual Health Inventory for Men score 11·1 to =13·7 nmol/l) had the lowest risk and there was a 78% increased risk for highest (>16·9 nmol/l) vs lowest (=8·6 nmol/l) quintile in Cox proportional hazards modelling (P = 0·036). Free serum testosterone and SHBG quintiles were not associated with death. Conclusions: These data provide some support for the general conventional serum testosterone

    Original languageEnglish
    Pages (from-to)444-452
    JournalClinical Endocrinology
    Issue number3
    Early online date5 May 2016
    Publication statusPublished - Sep 2016


    Cite this